The $180M Anti-Aging Pill Just Entered Human Trials (Sam Altman’s Retro)

Retro Biosciences, seeded with $180M from Sam Altman, has entered human Phase 1 trials with RTR242, an oral small molecule aimed at restoring lysosomal acidification and cellular autophagy. We break down the clinical trial design, how lysosomal recycling fails with age, and what human randomized trials reveal about mimetics like spermidine and Urolithin A.

🔬 Special Offer: Get 10% off Timeline Nutrition (Mitopure) for Mitophagy & Cellular Recycling: https://timeline.sjv.io/k4JrNx
Oxford Healthspan 15% off with MHS https://tinyurl.com/hrxfnzpn - Spermidine